Login / Signup

Application of furazolidone in Helicobacter pylori infection eradication.

Ying Ying HanJi Yan LiJia Lun GuanMei LiuPei Yuan Li
Published in: Journal of digestive diseases (2024)
Increasing antibiotic resistance is the primary reason for treatment failure of Helicobacter pylori (H. pylori) infection. To enhance the eradication rate, minimize the development of secondary resistance, and alleviate the socioeconomic burden, it is crucial to select H. pylori-sensitive antibiotics carefully. Furazolidone has been used for H. pylori eradication in developing countries for decades due to its affordability and low resistance rate. Numerous studies have demonstrated that furazolidone-containing regimens are more efficacious than those containing other antibiotics, as both first- and second-line therapies, and are also well tolerated. However, utility of furazolidone is restricted or not optimal in certain countries due to its infrequent but potentially severe adverse effects. The decision to discontinue usage of furazolidone because of concerns regarding adverse effects may be misguided. Here we comprehensively reviewed the studies on furazolidone at different dosages and treatment durations for H. pylori eradication. Further research on the mechanisms of action and clinical trials of furazolidone are of great practical importance.
Keyphrases
  • helicobacter pylori infection
  • helicobacter pylori
  • clinical trial
  • randomized controlled trial
  • combination therapy
  • case control
  • smoking cessation
  • decision making
  • phase iii